MIMETAS, a leader in human disease modeling, has unveiled OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. Launched at SLAS 2025, this innovative platform addresses key challenges in microphysiological systems by enabling realistic tissue models without the need for external pumps.

OrganoPlate UF supports up to 512 chips in a single setup, making it ideal for high-throughput screening in oncology, cardiovascular, and immunological research. By replicating natural blood circulation conditions, this platform enhances biological relevance while simplifying experimental workflows.

Key Features of OrganoPlate UF:

• Unidirectional, gravity-driven flow mimics natural blood circulation.
• Pump-free design reduces system complexity and improves ease of use.
• Scalable setup supports up to 512 chips, enabling high-throughput experiments.
• Long-term culture stability for chronic disease and therapeutic studies.
• Compatible with standard lab equipment for seamless integration into existing workflows.

OrganoPlate UF is already integrated into MIMETAS' liver, lung, brain, vasculature, and tumor models, advancing research in cancer, immunology, cardiovascular, and metabolic diseases.